Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
KRYS Stock Chart & Stats
$272.61
-$3.73(-2.33%)
At close: 4:00 PM EST
$272.61
-$3.73(-2.33%)
Day’s Range― - ―
52-Week Range$122.80 - $295.98
Previous CloseN/A
Volume44.50K
Average Volume (3M)276.40K
Market Cap
$7.91B
Enterprise Value$7.49B
Total Cash (Recent Filing)$731.07M
Total Debt (Recent Filing)$9.51M
Price to Earnings (P/E)40.9
Beta0.76
Next Earnings
Mar 02, 2026EPS Estimate
1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.66
Shares Outstanding28,997,519
10 Day Avg. Volume252,479
30 Day Avg. Volume276,402
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.73
Price to Sales (P/S)15.42
P/FCF Ratio37.58
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue20.08
Enterprise Value/Gross Profit21.39
Enterprise Value/Ebitda43.78
Forecast
1Y Price Target
$316.29Price Target Upside16.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionEx-U.S. launches of Vyjuvek in Europe and Japan combined with successful U.S. commercial execution support a multi-product rare disease strategy and potential revenue growth to fund pipeline advancement.
Gene Delivery ValidationNebulized KB407 produced widespread CFTR expression and demonstrable lung cell transduction, validating the inhaled HSV-1 platform's ability to reach target tissue and de-risking development for lung indications.
Regulatory PathwayRMAT designation for KB707 provides intensive FDA guidance and eligibility for priority review and accelerated approval, creating a clearer regulatory path that could speed potential market access.
Bears Say
Durability And Clinical TranslationUncertainty about durability of CFTR expression after redosing and the absence of conclusive lung function data leave open whether observed gene expression will translate into meaningful patient benefit.
Financial Pressure And DilutionProjected increases in research and selling expenses alongside potential increases in share count could pressure profitability and dilute per-share earnings.
Oncology Development RiskModest tumor response levels in some oncology settings and the early-stage status of KB707 introduce clinical and regulatory risk that could complicate approval prospects.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $122.80 and its highest was $295.98 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $7.91B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Mar 02, 2026 which is in 20 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Nov 03, 2025. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.09 by $1.57.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.55.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 28,997,519 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $2.66 in its last earnings report, beating expectations of $1.09. Following the earnings report the stock price went up 0.172%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$316.29 (16.02% Upside)
$316.29 (16.02% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 42.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.02%
12-Months-Change
Fundamentals
Return on Equity
19.66%
Trailing 12-Months
Asset Growth
26.24%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Krystal Biotech demonstrated strong financial performance with significant revenue growth and successful international expansion. However, challenges remain in achieving full market penetration and optimizing margins globally.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$316.29
▲(16.02% Upside)
Technical Analysis
Alkermes
―
PTC Therapeutics
―
Crispr Therapeutics AG
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
Currently, No data available
---